KR100864069B1 - 펩타이드 및/또는 단백질, 및 치료제 및 예방제의 제조를위한 그들의 용도 - Google Patents

펩타이드 및/또는 단백질, 및 치료제 및 예방제의 제조를위한 그들의 용도 Download PDF

Info

Publication number
KR100864069B1
KR100864069B1 KR1020037007799A KR20037007799A KR100864069B1 KR 100864069 B1 KR100864069 B1 KR 100864069B1 KR 1020037007799 A KR1020037007799 A KR 1020037007799A KR 20037007799 A KR20037007799 A KR 20037007799A KR 100864069 B1 KR100864069 B1 KR 100864069B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
arg
ndsk
residue
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037007799A
Other languages
English (en)
Korean (ko)
Other versions
KR20030060988A (ko
Inventor
페첼바우어페터
Original Assignee
피브렉스 메디칼 리서치 앤드 디벨롭먼트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피브렉스 메디칼 리서치 앤드 디벨롭먼트 게엠베하 filed Critical 피브렉스 메디칼 리서치 앤드 디벨롭먼트 게엠베하
Publication of KR20030060988A publication Critical patent/KR20030060988A/ko
Application granted granted Critical
Publication of KR100864069B1 publication Critical patent/KR100864069B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020037007799A 2000-12-12 2001-12-07 펩타이드 및/또는 단백질, 및 치료제 및 예방제의 제조를위한 그들의 용도 Expired - Fee Related KR100864069B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA2063/2000 2000-12-12
AT20632000 2000-12-12
PCT/AT2001/000387 WO2002048180A2 (de) 2000-12-12 2001-12-07 Peptide und/oder proteine sowie verwendung desselben zur herstellung eines therapeutischen und/oder präventiven arzneimittels

Publications (2)

Publication Number Publication Date
KR20030060988A KR20030060988A (ko) 2003-07-16
KR100864069B1 true KR100864069B1 (ko) 2008-10-16

Family

ID=3689750

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037007799A Expired - Fee Related KR100864069B1 (ko) 2000-12-12 2001-12-07 펩타이드 및/또는 단백질, 및 치료제 및 예방제의 제조를위한 그들의 용도

Country Status (30)

Country Link
US (4) US7271144B2 (enExample)
EP (2) EP1341819B1 (enExample)
JP (1) JP4181874B2 (enExample)
KR (1) KR100864069B1 (enExample)
CN (2) CN1518558B (enExample)
AT (2) ATE329614T1 (enExample)
AU (1) AU2002221316A1 (enExample)
BG (1) BG107891A (enExample)
BR (1) BR0116122A (enExample)
CA (1) CA2430972C (enExample)
CY (2) CY1106108T1 (enExample)
CZ (1) CZ20031630A3 (enExample)
DE (2) DE50114771D1 (enExample)
DK (2) DK1586586T3 (enExample)
EA (1) EA005576B1 (enExample)
EE (1) EE200300283A (enExample)
ES (2) ES2323963T3 (enExample)
HR (1) HRP20030564A2 (enExample)
HU (1) HUP0401536A3 (enExample)
IL (2) IL156360A0 (enExample)
MX (1) MXPA03005218A (enExample)
NO (1) NO330767B1 (enExample)
NZ (1) NZ550619A (enExample)
PL (2) PL209419B1 (enExample)
PT (2) PT1341819E (enExample)
SI (2) SI1586586T1 (enExample)
SK (1) SK7062003A3 (enExample)
WO (1) WO2002048180A2 (enExample)
YU (1) YU53803A (enExample)
ZA (1) ZA200304545B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430972C (en) 2000-12-12 2014-08-05 Fibrex Medical Research & Development Gmbh Fibrin fragments for treating inflammation
WO2006000007A1 (de) * 2004-06-25 2006-01-05 Fibrex Medical Research & Development Gesmbh Verwendung von peptiden, die aus der a alpha oder der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock
FR2879604B1 (fr) * 2004-12-22 2010-08-13 Biomerieux Sa Peptides citrullines derives de la fibrine reconnus par des auto-anticorps specifiques de la polyarthrite rhumatoide, et leurs utilisations
AT502987A1 (de) 2005-12-23 2007-07-15 Fibrex Medical Res & Dev Gmbh Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
CN101389653A (zh) 2006-02-23 2009-03-18 菲布雷克斯医疗研究及开发有限责任公司 肽和肽衍生物以及含有它们的药物组合物
WO2007095659A1 (de) * 2006-02-23 2007-08-30 Fibrex Medical Research & Development Gmbh Peptide und peptid-derivate, herstellun derselben sowie deren verwendung zur herstellung eines therapeutisch und/oder präventiv wirkenden arzneimittels
EP1987063B1 (en) * 2006-02-23 2009-09-23 Fibrex Medical Research & Development GmbH Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
FR2900657B1 (fr) * 2006-05-03 2009-04-17 Univ Toulouse Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
WO2009038729A2 (en) 2007-09-17 2009-03-26 Regenerx Biopharmaceuticals, Inc. Compositions and methods utilizing fibrin beta chain fragments of the bbeta chain of fibrinogen
FR2908134B1 (fr) * 2007-12-04 2012-10-12 Univ Toulouse 3 Paul Sabatier Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
WO2009096502A1 (ja) * 2008-01-31 2009-08-06 Japan As Represented By President Of National Center Of Neurology And Psychiatry うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断
US20090286725A1 (en) * 2008-05-15 2009-11-19 Fibrex Medical Research & Development Gmbh Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
US8088890B2 (en) 2008-09-26 2012-01-03 Fibrex Medical Research & Development Gmbh Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2010043444A2 (en) * 2008-10-15 2010-04-22 Fibrex Medical Research & Development Gmbh Pharmaceutical preparation for the treatment and/or prevention of ischemia/reperfusion injury and the sequels thereof
US20100152832A1 (en) * 2008-12-12 2010-06-17 Medtronic Vascular, Inc. Apparatus and Methods for Treatment of Aneurysms With Fibrin Derived Peptide B-Beta
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US12171802B2 (en) 2016-06-02 2024-12-24 University Of Maryland, Baltimore Compositions for inhibiting fibrin-VLDL receptor-dependent inflammation and methods of treatment
EP3912679A1 (en) * 2020-05-19 2021-11-24 Johann Wolfgang Goethe-Universität Frankfurt am Main Bbeta-15-42 for the treatment of viral endothelitis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927916A (en) 1984-04-23 1990-05-22 The General Hospital Corporation Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides
WO1993021962A1 (en) * 1992-04-30 1993-11-11 Diatech, Inc. TECHNETIUM-99m LABELED PEPTIDES FOR IMAGING
DE19729591A1 (de) * 1997-07-10 1999-02-11 Therasorb Medizinische Systeme Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2795735B1 (fr) * 1999-07-01 2001-09-07 Univ Toulouse Derives citrullines de la fibrine et leur utilisation pour le diagnostic ou le traitement de la polyarthrite rhumatoide
CA2430972C (en) * 2000-12-12 2014-08-05 Fibrex Medical Research & Development Gmbh Fibrin fragments for treating inflammation
US7201763B2 (en) * 2001-10-24 2007-04-10 Boston Scientific Scimed, Inc. Distal balloon waist material relief and method of manufacture

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927916A (en) 1984-04-23 1990-05-22 The General Hospital Corporation Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides
WO1993021962A1 (en) * 1992-04-30 1993-11-11 Diatech, Inc. TECHNETIUM-99m LABELED PEPTIDES FOR IMAGING
DE19729591A1 (de) * 1997-07-10 1999-02-11 Therasorb Medizinische Systeme Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen

Also Published As

Publication number Publication date
DK1341819T3 (da) 2006-10-16
CA2430972C (en) 2014-08-05
NO20032656D0 (no) 2003-06-12
EA200300678A1 (ru) 2003-10-30
ATE329614T1 (de) 2006-07-15
EP1586586A2 (de) 2005-10-19
JP4181874B2 (ja) 2008-11-19
US20090137464A1 (en) 2009-05-28
AU2002221316A1 (en) 2002-06-24
CN101676299A (zh) 2010-03-24
HUP0401536A3 (en) 2008-09-29
SI1586586T1 (sl) 2009-08-31
PL362924A1 (en) 2004-11-02
SK7062003A3 (en) 2003-11-04
ES2323963T3 (es) 2009-07-28
MXPA03005218A (es) 2004-12-03
EP1586586B1 (de) 2009-03-11
EP1341819B1 (de) 2006-06-14
EA005576B1 (ru) 2005-04-28
CA2430972A1 (en) 2002-06-20
KR20030060988A (ko) 2003-07-16
ATE425184T1 (de) 2009-03-15
ES2266093T3 (es) 2007-03-01
PL209419B1 (pl) 2011-08-31
US20090088384A1 (en) 2009-04-02
BG107891A (bg) 2004-08-31
CN1518558A (zh) 2004-08-04
JP2004527469A (ja) 2004-09-09
ZA200304545B (en) 2004-09-13
IL156360A0 (en) 2004-01-04
PL209752B1 (pl) 2011-10-31
US8067373B2 (en) 2011-11-29
HK1084400A1 (zh) 2006-07-28
NZ550619A (en) 2008-06-30
US20040192596A1 (en) 2004-09-30
EE200300283A (et) 2003-10-15
EP1586586A3 (de) 2006-03-29
PT1586586E (pt) 2010-05-28
CN1518558B (zh) 2010-06-16
WO2002048180A3 (de) 2003-01-30
WO2002048180A2 (de) 2002-06-20
CY1106108T1 (el) 2011-06-08
EP1341819A2 (de) 2003-09-10
HRP20030564A2 (en) 2005-06-30
US20070037749A1 (en) 2007-02-15
US7494973B2 (en) 2009-02-24
SI1341819T1 (sl) 2006-10-31
US7811985B2 (en) 2010-10-12
NO330767B1 (no) 2011-07-11
US7271144B2 (en) 2007-09-18
DE50110182D1 (de) 2006-07-27
BR0116122A (pt) 2003-10-14
YU53803A (sh) 2006-03-03
DK1586586T3 (da) 2009-06-29
IL156360A (en) 2012-12-31
CY1109107T1 (el) 2014-07-02
CZ20031630A3 (cs) 2003-10-15
NO20032656L (no) 2003-06-12
HUP0401536A2 (hu) 2004-11-29
PT1341819E (pt) 2006-10-31
DE50114771D1 (de) 2009-04-23

Similar Documents

Publication Publication Date Title
US7811985B2 (en) Therapeutic fibrin-derived peptides and uses thereof
CA2140543C (en) Thrombin receptor antagonists
DE69029579T2 (de) Inhibitoren der plättchen-aggregation
JP2004527469A6 (ja) ペプチドおよび／またはタンパク質、並びにその治療用および／または予防用医薬成分を調製するための使用
Shebuski et al. Demonstration of Ac-Arg-Gly-Asp-Ser-NH2 as an antiaggregatory agent in the dog by intracoronary administration
EP0298820A1 (fr) Nouveaux dérivés peptidiques et leur application notamment en thérapeutique
JP3930050B2 (ja) 平滑筋細胞増殖抑制能を有する新規ペプチド
CA2168964C (en) Novel peptide, and platelet aggregation-inhibiting agents, blood coagul ation-inhibiting agents for extracorporeal circulation, cell adhesion-inhibiting agents, tumor metastasis-inhibiting agents, agents for protecting platelet preparations for blood transfusion, platelet preparations and platelet preparation packs for transfusion using said novel peptides
US7094880B2 (en) Decorin proteoglycan inhibitor of fibrinogen blood clotting
HK1140212A (en) Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic pharmaceutical
JPH083065A (ja) 肝臓障害に対する治療剤
KR20160140147A (ko) 심장 허혈후 재관류 손상에 의한 심장 질환 치료 및 예방용 조성물
EP0701606A1 (en) Method of enhancing thrombolysis
HK1084400B (en) Peptide and/or proteins and their use for the manufacture of a therapeutic and/or preventive medicament

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20121005

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20130730

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20140728

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20151022

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20161011

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20161011